UCB Announces Start of Phase III Program With Epratuzumab for Patients With Moderate to Severe Systemic Lupus Erythematosus

Two Phase III Studies, EMBODY™ 1 and 2, Underway for Pipeline Drug Epratuzumab

Phase III Program Follows Positive Phase IIb Study EMBLEM™, Which Showed That Epratuzumab Reduced Disease Activity Over a 12-Week Treatment Period


MORRIS PLAINS, New Jersey and BRUSSELS, Dec. 14, 2010 (GLOBE NEWSWIRE) — Immunomedics Inc. (Nasdaq:IMMU) and UCB (EURONEXT:UCB) today announced the enrollment of [...] http://bit.ly/e6OPCR